A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers ...
The glioblastoma multiforme (GBM) treatment market size is on a steep growth trajectory, rising from $2.73 billion in 2025 to ...
In 2025, the market was valued at $2.7 billion, projected to reach $2.92 billion in 2026, with a CAGR of 8.1%. This ...
4don MSN
Breakthrough cancer drug shrinks deadly brain tumour in just 5 days, study shows promising results
A new CAR-T cell therapy has shown promising early results against glioblastoma, a highly aggressive brain cancer. In a phase ...
Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma Leronlimab ...
BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that researchers will ...
Half of patients with GBM present with headaches at diagnosis, which is attributed to increases in intracranial pressure (Table 2). 11 Papilledema, now rarely seen because imaging is typically ...
Opinion
Los Angeles Times on MSNOpinion
Contributor: Being insured in America is not the same as having access to care
Privilege in healthcare is shaped by geography, timing and a patient's ability to navigate an unforgiving system while in crisis.
Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results